Mitochondrial translational inhibitors in the pharmacopeia

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1819, Issue 9-10, 2012, Pages 1067-1074

  Cohen, Bruce H ^a   Saneto, Russell P ^b  

^a AKRON CHILDREN'S HOSPITAL   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

Antibiotic toxicity; Bacterial ribosome; Mitochondrial DNA; Mitochondrial ribosome; Mitochondrial translation

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CELL NUCLEUS DNA; CHLORAMPHENICOL; ERYTHROMYCIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; MITOCHONDRIAL DNA; OXAZOLIDINONE DERIVATIVE; STREPTOGRAMIN DERIVATIVE; TETRACYCLINE DERIVATIVE;

ACNE; ALPHAPROTEOBACTERIA; ANTHRAX; ANTIBIOTIC RESISTANCE; APOPTOSIS; BACTERIAL CLEARANCE; BACTERIAL EYE INFECTION; BACTERIAL SKIN DISEASE; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BRUCELLOSIS; DRUG EFFICACY; DRUG SAFETY; EAR INFECTION; GENE MUTATION; GENE PRODUCT; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HAEMOPHILUS INFECTION; HEARING LOSS; HUMAN; LACTIC ACIDOSIS; LYME DISEASE; MENINGOCOCCOSIS; MISSENSE MUTATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL TOXICITY; MITOCHONDRIAL TRANSLATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPTIC NERVE DISEASE; OTOTOXICITY; OXIDATIVE PHOSPHORYLATION; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PLAGUE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; ROCKY MOUNTAIN SPOTTED FEVER; SINUSITIS; SKIN INFECTION; TRANSLATION INITIATION;

AMINOGLYCOSIDES; BACTERIA; CHLORAMPHENICOL; DNA, MITOCHONDRIAL; HUMANS; MACROLIDES; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; PROTEIN BIOSYNTHESIS; RNA, RIBOSOMAL, 16S; TETRACYCLINES;

ALPHAPROTEOBACTERIA; BACTERIA (MICROORGANISMS);

EID: 84864309995     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2012.02.023     Document Type: Review

References (85)

1. Cohen B.H. Pharmacologic effects on mitochondrial function. Dev. Disabil. Res. Rev. 2010, 16:189-199.
2. Wallace D.C. Why do we have a maternally inherited mitochondrial DNA? Insights from evolutionary medicine. Annu. Rev. Biochem. 2008, 76:781-821.
3. Martin W., Hoffmeister M., Rotte C., Henze K. An overview of endosymbiotic models for the origins of eukaryotes, their ATP-producing organelles (mitochondria and hydrogenosomes), and their heterotrophic lifestyle. Biol. Chem. 2001, 382:1521-1539.
4. Wong L.-J. C. molecular genetics of mitochondrial disorders. Dev. Disabil. Res. Rev. 2010, 16:154-162.
5. Richter C., Park J.W., Ames B.N. Normal oxidative damage to nuclear DNA is extensive. Proc. Natl. Acad. Sci. 1988, 85:6465-6467.
6. DiMauro S., Garone C. Historical perspective of mitochondrial medicine. Dev. Disabil. Res. Rev. 2010, 16:106-113.
7. Wallace D.C. Bioenergetics and the epigenome: interface between the environment and genes in common diseases. Dev. Disabil. Res. Rev. 2010, 16:114-119.
8. Sato M., Sato K. Degradation of paternal michondria by fertilization-triggered autophagy in C. elegans embryos. Science 2011, 334:1141-1144.
9. Al Rawi S., Louvet-Vallee S., Djeddi A., Sachae M., Culetto E., Hajjar C., Boyd L., Legouris R., Galy V. Postfertilization autophagy of sperm organelles prevents paternal mitochondrial DNA transmission. Science 2011, 334:1144-1147.
10. West P., Shadel G.S., Ghosh S. Mitochondria in innate immune responses. Nat. Rev. 2011, 11:389-402.
11. Scott I. The role of mitochondria in the mammalian antiviral defense system. Mitochondrion 2010, 10:316-320.
12. Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., Brohi K., Itagaki K., Hauser C.J. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107.
13. Parikh S. The neurological effects of mitochondrial disease. Dev. Disabil. Res. Rev. 2010, 16:120-128.
14. Haas R.H., Parikh S., Falk M.H., Saneto R.P., Wolf N.I., Darin N., Wong L.-J., Cohen B.H., Naviaux R.K. The in-depth evaluation of suspected mitochondrial disease. Mol. Genet. Metab. 2008, 94:16-37.
15. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J. Neurol. Neurosurg. Psychiatry 1951, 14:216-221.
16. Kearns T.P., Sayre G.P. Retinitis pigmentosa, external ophthalmoplegia, and complete heart block: unusual syndrome with histologic study in one of two cases. Arch. Ophthalmol. 1958, 60:280-289.
17. Luft R., Ikkos D., Palmieri G., Ernster L., Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J. Clin. Invest. 1962, 41:1776-1804.
18. Holt I.J., Harding A.E., Morgan Hughes J.A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988, 331:717-719.
19. Wallace D.C., Singh G., Lott M.T., Hodge J.A., Schurr T.G., Lezza A.M., Elsas L.H., Nikoskelainen E.K. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988, 242:1427-1430.
20. Tuppen H.A.L., Blakely E.L., Turnbull D.M., Taylor R.W. Mitochondrial DNA mutations and human disease. Biochim. Biophys. Acta 2010, 1797:113-128.
21. Parkih S., Saneto R., Falk M.J., Anslem I., Cohen B.H., Haas R. A modern approach to the treatment of mitochondrial diseases. Curr. Treat. Options Neurol. 2009, 11:414-430.
22. Prezant T.R., Agapian J.V., Bohlman M.C., Bu X., Oztas S., Qiu W.Q., Arnos K.S., Cortopassi G.A., Jaber L., Rotter J.I., Mordechal S., Fischel-Ghodsian F. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat. Genet. 1993, 4:289-294.
23. Goto Y., Nonaka I., Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990, 348:651-653.
24. Shoffner J.M., Lott M.T., Lezza A., Seibel P., Ballinger S.W., Wallace D.C. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNALys mutation. Cell 1990, 61:931-937.
25. Schon E.A., Hirano M., DiMauro S. Drug effects with mitochondrial diseases. Drug-Induced Mitochondrial Dysfunction 2008, 311-324. Wiley, Hobokin. J.A. Dykens, Y. Will (Eds.).
26. O'Brien T.W. Properties of human mitochondrial ribosomes. IUBMB Life 2003, 55:505-513.
27. Tenson T., Mankin A. Antibiotics and the ribosome. Mol. Microbiol. 2006, 59:1664-1677.
28. Maaloe O. Regulation of the protein synthesis machinery. Biological Regulation and Development 1979, Vol 1:487-542. Plenum Publishing Corp., NY. R.F. Goldberg (Ed.).
29. Wolstenholme D.R. Animal mitochondrial DNA: structure and evolution. Mitochondrial Genomics 1992, 173-216. Academic Press, San Diego, CA. D.R. Wolstenholme, K.W. Jeong (Eds.).
30. O'Brien T.W., O'Brien B.J., Norman R.A. Nuclear MRP genes and mitochondrial disease. Gene 2005, 354:147-151.
31. Smits P., Smeitink J., van den Heuvel L. Mitochondrial translation and beyond: processes implicated in combined oxidative phosphorylation deficiencies. J. Biomed. Biotechnol. 2010, 2010:737385.
32. Franceschi F. Back to the future: the ribosome as an antibiotic target. Future Microbiol. 2007, 571-574.
33. Gonzalez L.S., Spencer J.P. Aminoglycosides: a practical review. Am. Fam. Physician 1998, 58:1811-1820.
34. Henley CM, Schacht J, Pharmacokinetic of aminoglycoside antibiotics in blood, inner-ear fluids and tissues and their relationship to ototoxicity, Audiology. 27 (1088) 137-146.
35. Elliott H.R., Samuels D.C., Eden J.A., Relton C.L., Chinnery P.F. Pathogenic mitochondrial DNA mutations are common in the general population. Am. J. Hum. Genet. 2008, 83:254-260.
36. Chen G., Wang X., Fu S. Prevalence of A1555G mitochondrial mutation in Chinese newborns and the correlation with neonatal hearing screening. Int. J. Pediatr. Otorhinolaryngol. 2011, 75:532-534.
37. Vandebona H., Mitchell P., Manwaring N., Griffiths K., Gopinath B., Wang J.J., Sue C.M. Prevalence of mitochondrial 1555A->G mutation in adults of European descent. N. Engl. J. Med. 2009, 360:642-644.
38. Bitner-Glindzicz M., Pembrey M., Duncan A., Heron J., Ring S.M., Hall A., Rahman S. Prevalence of mitochondrial 1555A->G mutation in European children. N. Engl. J. Med. 2009, 360:640-642.
39. Cai J., Luo C.Q., Xie J.S., Wu W.Q., Geng Q., Xu Z.Y., Hao Y., Xu X.X. Clinical significance of large-scale screening of A1555G mutation of mitochondria DNA for neonates. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011, 28:414-416.
40. Tang H.Y., Hutcheson E., Neill S., Drummond-Borg M., Speer M., Alford R.L. Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk?. Genet. Med. 2002, 4:336-345.
41. Hutchin T. Sensorineural hearing loss and the 1555G mitochondrial DNA mutation. Acta Otolaryngol. 1999, 119:48-52.
42. Rydzanicz M., Wróbel M., Pollak A., Gawecki W., Brauze D., Kostrzewska-Poczekaj M., Wojsyk-Banaszak I., Lechowicz U., Mueller-Malesińska M., Ołdak M., Płoski R., Skarzyński H., Szyfter K. Mutation analysis of mitochondrial 12S rRNA gene in Polish patients with non-syndromic and aminoglycoside-induced hearing loss. Biochem. Biophys. Res. Commun. 2010, 395:116-121.
43. Fischel-Ghodsian N., Prezant T.R., Chaltraw W.E., Wendt K.A., Nelson R.A., Arnos K.S., Falk R.E. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am. J. Otolaryngol. 1997, 18:173-178.
44. Qi Y., Zhang Y., Wang Z., Yang Y., Yuan Y., Niu S., Pei P., Wang S., Ma Y., Bu D., Zou L., Fang F., Xiao J., Sun F., Zhang Y., Wu Y., Wang S., Xiong H., Wu X. Screening of common mitochondrial mutations in Chinese patients with mitochondrial encephalomyopathies. Mitochondrion 2007, 7:147-150.
45. Ballana E., Morales E., Rabionet R., Montserrat B., Ventayol M., Bravo O., Gasparini P., Estivill X. Mitochondrial 12S rRNA gene mutations affect RNA secondary structure and lead to variable penetrance in hearing impairment. Biochem. Biophys. Res. Commun. 2006, 341:950-957.
46. Zhao H., Li R., Wang Q., Yan Q., Deng J.H., Han D., Bai Y., Young W.Y., Guan M.X. Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family. Am. J. Hum. Genet. 2004, 74:139-152.
47. Yang A.F., Zheng J., Lv J.X., Guan M.X. Modifier factors influencing the phenotypic manifestation of the deafness associated mitochondrial DNA mutations. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011, 28:165-171.
48. Guan M.X., Yan Q., Li X., Bykhovskaya Y., Gallo-Teran J., Hajek P., Umeda N., Zhao H., Garrido G., Mengesha E., Suzuki T., del Castillo I., Peters J.L., Li R., Qian Y., Wang X., Ballana E., Shohat M., Lu J., Estivill X., Watanabe K., Fischel-Ghodsian N. Mutation in TRMU related to transfer RNA modification modulates the phenotypic expression of the deafness-associated mitochondrial 12S ribosomal RNA mutations. Am. J. Hum. Genet. 2006, 79:291-302.
49. Zeharia A., Shaag A., Pappo O., Mager-Heckel A.M., Saada A., Beinat M., Karicheva O., Mandel H., Ofek N., Segel R., Marom D., Ror̈tig A., Tarassov I., Elpeleg O. Acute infantile liver failure due to mutations in the TRMU gene. Am. J. Hum. Genet. 2009, 85:401e7.
50. Bykhovskaya Y., Mengesha E., Wang D., Yang H., Estivill X., Shohat M., Fischel Ghodsian N. Human mitochondrial transcription factor B1 as a modifier gene for hearing loss associated with the mitochondrial A1555G mutation. Mol. Genet. Metab. 2004, 82:27-32.
51. Cotney J., McKay S.E., Shadel G.S. Elucidation of separate, but collaborative functions of the rRNA methyltransferase-related human mitochondrial transcription factors B1 and B2 in mitochondrial biogenesis reveals new insight into maternally inherited deafness. Hum. Mol. Genet. 2009, 15:2670-2682.
52. Roberts M.C. Tetracycline therapy: update. Clin. Infect. Dis. 2003, 15:462-467.
53. Cuenca-Lopez M.D., Karachitos A., Massarotto L., Oliveira P.J., Aguirre N., Galindo M.F., Kmita H., Jordán J. Minocycline exerts uncoupling and inhibiting effects on mitochondrial respiration through adenine nucleotide translocase inhibition. Pharmacol. Res. 2011 Aug 22, [Epub ahead of print] PubMed PMID: 21884796.
54. Sourdeval M., Lemaire C., Brenner C., Boisvieux-Ulrich E., Marano F. Mechanisms of doxycycline-induced cytotoxicity on human bronchial epithelial cells. Front. Biosci. 2006, 11:3036-3048.
55. Chopra I., Roberts M. Tetracycline antibiotics: mode of action, application, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 2001, 65:232-260.
56. van den Bogert C., Kroon A.M. Tissue distribution and effects on mitochondrial protein synthesis of tetracyclines after prolonged continuous intravenous administration to rats. Biochem. Pharmacol. 1981, 30:1706-1709.
57. Burk A., Douzery E.J.P., Sriger M.S. The secondary structure of mammalian mitochondrial 16S rRNA molecules: refinements based upon a comparative phylogenetic approach. J. Mammal. Evol. 2001, 9:225-243.
58. Nitzan O., Suponitzky U., Kennes Y., Chazan B., Raul R., Colodner R. Is chloramphenicol making a comeback?. Isr. Med. Assoc. J. 2010, 12:371-374.
59. Yunis A.A. Chloramphenicol toxicity: 25years of research. Am. J. Med. 1989, 87:44N-48N.
60. Wallerstein R., Condit P., Kasper C., Brown J., Morrison F. Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA 1969, 208:2045-2050.
61. Feder H.M. Chloramphenicol: what we have learned in the last decade. South Med. J. 1986, 79:1129-1134.
62. Nagao T., Mauer A.M. Concordance for drug-induced aplastic anemia in identical twins. N. Engl. J. Med. 1969, 281:7-11.
63. Prigione A., Cortopassi G. Mitochondrial DNA deletions and chloramphenicol treatment stimulate the autophagic transcript ATG12. Autophagy 2007, 3:377-380.
64. de Wildt S.N., Kearns G.L., Leeder J.S., van den Anker J.N. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin. Phamacokinet. 1999, 36:439-452.
65. McKee E.E., Ferguson M., Bentley A.T., Marks T.A. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 2006, 50:2042-2049.
66. Tenson T., Lovmar M., Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J. Mol. Biol. 2003, 330:1005-1014.
67. Luca C.C., Lam B.L., Moraes C.T. Erythromycin as a potential precipitating agent in the onset of Leber's hereditary optic neuropathy. Mitochondrion 2004, 4:31-36.
68. Leach K.L., Swaney S.M., Colca J.R., McDonald W.G., Blinn J.R., Thomasco L.M., Gadwood R.C., Shinabarger D., Xiong L., Mankin A.S. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell. 2007, 26:393-402.
69. Bernstein W.B., Trotta R.F., Rector J.T., Tjaden J.A., Barile A.J. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann. Pharmacother. 2003, 37:517-520.
70. Taketani T., Kanai R., Fukuda S., Uchida Y., Yasuda K., Mishima S., Suyama T., Kodama R., Yoshino I., Kunishi H., Yamaguchi S., Masuda J. Pure red cell precursor toxicity by linezolid in a pediatric case. J. Pediatr. Hematol. Oncol. 2009, 31:684-686.
71. Apodaca A.A., Rakita R.M. Linezolid-induced lactic acidosis. N. Engl. J. Med. 2003, 348:86-87.
72. Beekmann S.E., Gilbert D.N., Polgreen P.M. IDSA emerging infections network. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn. Microbiol. Infect. Dis. 2008, 62:407-410.
73. Lee E., Burger S., Shah J., Melton C., Mullen M., Warren F., Press R. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin. Infect. Dis. 2003, 37:1389-1391.
74. Narita M., Tsuji B.T., Yu V.L. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007, 27:1189-1197.
75. Hainrichson M., Nudelman I., Baasov T. Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic Diseases. Org. Biomol. Chem. 2008, 6:227-239.
76. Pokrovskaya V., Nudelman I., Kandasamy J., Baasov T. Aminoglycosides redesign strategies for improved antibiotics and compounds for treatment of human genetic diseases. Methods Enzymol. 2010, 478:437-462.
77. Wimberly B.T. The use of ribosomal crystal structures in antibiotic drug design. Curr. Opin. Investig. Drugs 2009, 10:750-765.
78. Nagiec E.E., Wu L., Swaney S.M., Chosay J.G., Ross D.E., Brieland J.K., Leach K.L. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob. Agents Chemother. 2005, 49:3896-3902.
79. De Vriese A.S., Coster R.V., Smet J., Seneca S., Lovering A., Van Haute L.L., Vanopdenbosch L.J., Martin J.J., Groote C.C., Vandecasteele S., Boelaert J.R. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. 2006, 42:1111-1117.
80. Locke J.B., Finn J., Hilgers M., Morales G., Rahawi S., G C K, Picazo J.J., Im W., Shaw K.J., Stein J.L. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob. Agents Chemother. 2010, 54:5337-5343.
81. Chomyn A. In vivo labeling and analysis of human mitochondrial translation products. Methods Enzymol. 1996, 264:197-211.
82. Scheinfeld N. Tigecycline: a review of a new glycylcycline antibiotic. J. Dermatolog. Treat. 2005, 16:207-212.
83. Skrtić M., Sriskanthadevan S., Jhas B., Gebbia M., Wang X., Wang Z., Hurren R., Jitkova Y., Gronda M., Maclean N., Lai C.K., Eberhard Y., Bartoszko J., Spagnuolo P., Rutledge A.C., Datti A., Ketela T., Moffat J., Robinson B.H., Cameron J.H., Wrana J., Eaves C.J., Minden M.D., Wang J.C., Dick J.E., Humphries K., Nislow C., Giaever G., Schimmer A.D. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 2011, 20:674-688.
84. Järås M., Ebert B.L. Power cut: inhibiting mitochondrial translation to target leukemia. Cancer Cell 2011, 20:555-556.
85. Nguyen K.V., Østergaard E., Ravn S.H., Balslev T., Danielsen E.R., Vardag A., McKiernan P.J., Gray G., Naviaux R.K. Neurology 2005, 8:1493-1495.